Matuzumab news from FierceBiotech
NewsMatuzumab in doubt after trial failure
There's trouble at Merck Serono's program for Matuzumab, which is in development for colorectal cancer. Merck KGaA says it is "reconsidering" further development of the therapy after the... Read more...
| Press ReleasesPRESS RELEASE: Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients DARMSTADT, Germany, August 29, 2007 - Merck Serono, a division of Merck KGaA, announced today that a Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
